Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal postpartum withdrawal timing of tenofovir to prevent mother-to-child transmission of hepatitis B virus
ChiCTR-IPR-17011922Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir in Chronic Hepatitis B (CHB) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Successful mother-to-child transmission prevention rate of HBV. Started Jul 2017; status: recruiting.
02
Drugs
tenofovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-IPR-17011922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011922.